A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent

Chi-Tai Yeh, Chun Li Su, Chi Ying F Huang, Justin Kung Yi Lin, Wei Hwa Lee, Peter M H Chang, Yu Lun Kuo, Yu Wen Liu, Liang Shun Wang, Chih Hsiung Wu, Yi Shing Shieh, Yi Hua Jan, Yung Jen Chuang, Michael Hsiao, Alexander T H Wu

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Drug resistance and tumor recurrence are major obstacles in treating lung cancer patients. Accumulating evidence considers lung cancer stem cells (CSCs) as the major contributor to these clinical challenges. Agents that can target lung CSCs could potentially provide a more effective treatment than traditional chemotherapy. Here, we utilized the side-population (SP) method to isolate lung CSCs from A549 and PC-9 cell lines. Subsequently, a high throughput platform, connectivity maps (CMAPs), was used to identify potential anti-CSC agents. An antibiotic, antimycin A (AMA), was identified as a top candidate. SP A549 cells exhibited an elevated stemness profile, including Nanog, β-catenin, Sox2, and CD133, and increased self-renewal ability. AMA treatment was found to suppress β-catenin signaling components and tumor sphere formation. Furthermore, AMA treatment decreased the proliferation of gefitinib-resistant PC-9/GR cells and percentage of SP population. AMA demonstrated synergistic suppression of PC-9/GR cell viability when combined with gefitinib. Finally, AMA treatment suppressed tumorigenesis in mice inoculated with A549 SP cells. Collectively, we have identified AMA using CMAP as a novel antilung CSC agent, which acts to downregulate β-catenin signaling. The combination of AMA and targeted therapeutic agents could be considered for overcoming drug resistance and relapse in lung cancer patients.

Original languageEnglish
Article number910451
JournalEvidence-based Complementary and Alternative Medicine
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Antimycin A
Neoplastic Stem Cells
Side-Population Cells
Lung Neoplasms
Catenins
Drug Resistance
Therapeutics
Recurrence
antimycin
Population
Neoplasms
Cell Survival
Carcinogenesis
Down-Regulation
Anti-Bacterial Agents
Drug Therapy
Cell Line

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent. / Yeh, Chi-Tai; Su, Chun Li; Huang, Chi Ying F; Lin, Justin Kung Yi; Lee, Wei Hwa; Chang, Peter M H; Kuo, Yu Lun; Liu, Yu Wen; Wang, Liang Shun; Wu, Chih Hsiung; Shieh, Yi Shing; Jan, Yi Hua; Chuang, Yung Jen; Hsiao, Michael; Wu, Alexander T H.

In: Evidence-based Complementary and Alternative Medicine, Vol. 2013, 910451, 2013.

Research output: Contribution to journalArticle

Yeh, C-T, Su, CL, Huang, CYF, Lin, JKY, Lee, WH, Chang, PMH, Kuo, YL, Liu, YW, Wang, LS, Wu, CH, Shieh, YS, Jan, YH, Chuang, YJ, Hsiao, M & Wu, ATH 2013, 'A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent', Evidence-based Complementary and Alternative Medicine, vol. 2013, 910451. https://doi.org/10.1155/2013/910451
Yeh, Chi-Tai ; Su, Chun Li ; Huang, Chi Ying F ; Lin, Justin Kung Yi ; Lee, Wei Hwa ; Chang, Peter M H ; Kuo, Yu Lun ; Liu, Yu Wen ; Wang, Liang Shun ; Wu, Chih Hsiung ; Shieh, Yi Shing ; Jan, Yi Hua ; Chuang, Yung Jen ; Hsiao, Michael ; Wu, Alexander T H. / A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent. In: Evidence-based Complementary and Alternative Medicine. 2013 ; Vol. 2013.
@article{79183767242945fb917e16b1c457f59f,
title = "A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent",
abstract = "Drug resistance and tumor recurrence are major obstacles in treating lung cancer patients. Accumulating evidence considers lung cancer stem cells (CSCs) as the major contributor to these clinical challenges. Agents that can target lung CSCs could potentially provide a more effective treatment than traditional chemotherapy. Here, we utilized the side-population (SP) method to isolate lung CSCs from A549 and PC-9 cell lines. Subsequently, a high throughput platform, connectivity maps (CMAPs), was used to identify potential anti-CSC agents. An antibiotic, antimycin A (AMA), was identified as a top candidate. SP A549 cells exhibited an elevated stemness profile, including Nanog, β-catenin, Sox2, and CD133, and increased self-renewal ability. AMA treatment was found to suppress β-catenin signaling components and tumor sphere formation. Furthermore, AMA treatment decreased the proliferation of gefitinib-resistant PC-9/GR cells and percentage of SP population. AMA demonstrated synergistic suppression of PC-9/GR cell viability when combined with gefitinib. Finally, AMA treatment suppressed tumorigenesis in mice inoculated with A549 SP cells. Collectively, we have identified AMA using CMAP as a novel antilung CSC agent, which acts to downregulate β-catenin signaling. The combination of AMA and targeted therapeutic agents could be considered for overcoming drug resistance and relapse in lung cancer patients.",
author = "Chi-Tai Yeh and Su, {Chun Li} and Huang, {Chi Ying F} and Lin, {Justin Kung Yi} and Lee, {Wei Hwa} and Chang, {Peter M H} and Kuo, {Yu Lun} and Liu, {Yu Wen} and Wang, {Liang Shun} and Wu, {Chih Hsiung} and Shieh, {Yi Shing} and Jan, {Yi Hua} and Chuang, {Yung Jen} and Michael Hsiao and Wu, {Alexander T H}",
year = "2013",
doi = "10.1155/2013/910451",
language = "English",
volume = "2013",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - A preclinical evaluation of antimycin a as a potential antilung cancer stem cell agent

AU - Yeh, Chi-Tai

AU - Su, Chun Li

AU - Huang, Chi Ying F

AU - Lin, Justin Kung Yi

AU - Lee, Wei Hwa

AU - Chang, Peter M H

AU - Kuo, Yu Lun

AU - Liu, Yu Wen

AU - Wang, Liang Shun

AU - Wu, Chih Hsiung

AU - Shieh, Yi Shing

AU - Jan, Yi Hua

AU - Chuang, Yung Jen

AU - Hsiao, Michael

AU - Wu, Alexander T H

PY - 2013

Y1 - 2013

N2 - Drug resistance and tumor recurrence are major obstacles in treating lung cancer patients. Accumulating evidence considers lung cancer stem cells (CSCs) as the major contributor to these clinical challenges. Agents that can target lung CSCs could potentially provide a more effective treatment than traditional chemotherapy. Here, we utilized the side-population (SP) method to isolate lung CSCs from A549 and PC-9 cell lines. Subsequently, a high throughput platform, connectivity maps (CMAPs), was used to identify potential anti-CSC agents. An antibiotic, antimycin A (AMA), was identified as a top candidate. SP A549 cells exhibited an elevated stemness profile, including Nanog, β-catenin, Sox2, and CD133, and increased self-renewal ability. AMA treatment was found to suppress β-catenin signaling components and tumor sphere formation. Furthermore, AMA treatment decreased the proliferation of gefitinib-resistant PC-9/GR cells and percentage of SP population. AMA demonstrated synergistic suppression of PC-9/GR cell viability when combined with gefitinib. Finally, AMA treatment suppressed tumorigenesis in mice inoculated with A549 SP cells. Collectively, we have identified AMA using CMAP as a novel antilung CSC agent, which acts to downregulate β-catenin signaling. The combination of AMA and targeted therapeutic agents could be considered for overcoming drug resistance and relapse in lung cancer patients.

AB - Drug resistance and tumor recurrence are major obstacles in treating lung cancer patients. Accumulating evidence considers lung cancer stem cells (CSCs) as the major contributor to these clinical challenges. Agents that can target lung CSCs could potentially provide a more effective treatment than traditional chemotherapy. Here, we utilized the side-population (SP) method to isolate lung CSCs from A549 and PC-9 cell lines. Subsequently, a high throughput platform, connectivity maps (CMAPs), was used to identify potential anti-CSC agents. An antibiotic, antimycin A (AMA), was identified as a top candidate. SP A549 cells exhibited an elevated stemness profile, including Nanog, β-catenin, Sox2, and CD133, and increased self-renewal ability. AMA treatment was found to suppress β-catenin signaling components and tumor sphere formation. Furthermore, AMA treatment decreased the proliferation of gefitinib-resistant PC-9/GR cells and percentage of SP population. AMA demonstrated synergistic suppression of PC-9/GR cell viability when combined with gefitinib. Finally, AMA treatment suppressed tumorigenesis in mice inoculated with A549 SP cells. Collectively, we have identified AMA using CMAP as a novel antilung CSC agent, which acts to downregulate β-catenin signaling. The combination of AMA and targeted therapeutic agents could be considered for overcoming drug resistance and relapse in lung cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84880178312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880178312&partnerID=8YFLogxK

U2 - 10.1155/2013/910451

DO - 10.1155/2013/910451

M3 - Article

VL - 2013

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 910451

ER -